Insiders · BGMS

Mark Kirschbaum

Officer at Cyclacel Pharmaceuticals, Inc. (BGMS)

Mark Kirschbaum has filed 3 insider reports with the SEC since December 2021, as officer at Cyclacel Pharmaceuticals, Inc. (BGMS). The latest filing, on July 3, 2023, reports grant or award at Cyclacel Pharmaceuticals, Inc. (BGMS).

Filings
3
Companies
1
Bought on market
None
Sold on market
None

Companies where Mark Kirschbaum is an insider

CompanyRoleShares heldBoughtSoldAvg buyPrice nowLast filing
Cyclacel Pharmaceuticals, Inc. logo
BGMS
Cyclacel Pharmaceuticals, Inc.
Officer31,200$0.6109Jul 3, 2023

Shares held: common shares owned directly after the latest filing that states it. Avg buy: open-market purchase dollars divided by shares bought, every filing on record.

Every filing

Compare Mark Kirschbaum with

Other insiders at the same companies

Questions about Mark Kirschbaum

What is Mark Kirschbaum's role at Cyclacel Pharmaceuticals, Inc.?
Mark Kirschbaum reports to the SEC as officer at Cyclacel Pharmaceuticals, Inc. (BGMS), according to the latest filing on July 3, 2023.
How many shares does Mark Kirschbaum own?
After the latest filing that states it, Mark Kirschbaum directly owned 31,200 shares of Cyclacel Pharmaceuticals, Inc. (BGMS). Shares held through trusts, funds or family members are reported separately and are not counted here.
Has Mark Kirschbaum bought or sold stock recently?
No open-market purchases or sales by Mark Kirschbaum are on file. The filings report grant or award.
How do I get alerts when Mark Kirschbaum files?
Follow Mark Kirschbaum on Quantisnow and you get an email, and a phone notification on Plus, within minutes of each new Form 4 or Form 5, and of each Form 144 notice of a planned sale.

From SEC Forms 3, 4, 5 and 144 filed by Mark Kirschbaum (SEC CIK 0001830211). Totals count each trade once, skipping amendments whose original is on file, from Dec 15, 2021 on. View on SEC EDGAR · Get this as JSON